// App-Quantinova.ai

: Elevated C-Reactive Protein Level Amplifies the Association of Lipoprotein(a) With Cardiovascular Risk and Risk Reduction With Alirocumab After Acute Coronary Syndrome

Researchers

Presenter

  • Gregory G Schwartz

Principal Investigators

  • Michael Szarek

  • Deepak Bhatt

  • Vera A Bittner

  • Rafael Diaz

  • Genevive Garon

  • Shaun G Goodman

  • Robert A Harrington

  • J Wouter W Jukema

  • Garen Manvelian

  • Robert Pordy

  • Harvey D White

  • Andreas M Zeiher

  • Philippe G Steg

Medical Centers

  • Regeneron, Tarrytown, NY, USA

  • Brigham & Women's Hospital, Boston, MA

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • St Michael's Hospital, University of Toronto, Toronto, ON, Canada

  • ECLA International, Rosario, Argentina

  • Auckland City Hosp, Auckland

  • Hopital Bichat, Paris, France

  • Radiology, Univ of Colorado Sch of Medicine, Aurora, CO

  • University of Alabama at Birmingham, Birmingham, AL

  • Sanofi Canada, Laval, Canada

  • Leiden Univ Med Cntr, Leiden

  • Klinikum d. J. W Goethe-Universitat, Frankfurt

  • SUNY Downstate Sch of Public Health, Brooklyn, NY

Locations

  • Netherlands

  • France

  • New Zealand

  • United States

  • Canada

  • Argentina

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Central Nervous System (CNS)

Disease

  • Acute Coronary Syndromes

  • Venous thrombosis

  • Angina

  • Congestive heart failure

  • Coronary Artery Disease

  • Stroke

Biomarkers

  • C reactive protein

  • Nucleoside diphosphate kinase A

  • High sensitivity C-reactive protein

Drug/Treatment

  • Alirocumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • N/A

Study Id's

  • NCT01663402

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved